On December 10, the signing ceremony of E-nitiate Biopharmaceuticals
settlement and Betta fund strategic investment was successfully held in
Yuhang District, Hangzhou. Zhu Zhenwei, member of the Standing Committee
of Yuhang District Party committee, Secretary of the Party Working
Committee and director of the Management Committee of the Development
Zone, Dr. Ding lieming, chairman and CEO of Betta pharmaceutical and
founder of Betta fund, and Dr. Shen Wang, chairman and chief scientist
of E-nitiate Biopharmaceuticals attended the ceremony.
E-nitiate Biopharmaceuticals is a key introduction project of Yuhang Economic and Technological Development Zone. The company is committed to the research and development of new drugs for autoimmune diseases. The core team is led by Dr. Shen Wang, a senior scientist, and composed of many overseas returnees with rich experience in clinical development and commercialization. The company has a number of innovative drugs independently developed, and the clinical application of QY201 in the R & D pipeline is imminent. Recently, the company acquired tens of millions of yuan in angel round investment from Betta fund.
Mr.
Zhu Zhenwei, member of the Standing Committee of Yuhang District Party
committee, Secretary of the Party Working Committee and director of the
Management Committee of the Development Zone, welcomed the settlement of
E-nitiate Biopharmaceuticals in Yuhang Economic and Technological
Development Zone. He said that E-nitiate Biopharmaceuticals, led by Dr.
Shen Wang, an overseas high-level talent, is a pharmaceutical innovation
company with great development potential, which will inject strong
impetus into the high-quality development of the development zone. In
the future, Yuhang Economic and Technological Development Zone will
continue to optimize the business environment within its jurisdiction,
stimulate the vitality of market players, and provide maximum support
for enterprise innovation and talent introduction. I wish E-nitiate
Biopharmaceuticals as a "Star" to shine on its future development path.
Speech by secretary Zhu Zhenwei
Dr. Ding Lieming, chairman and CEO of Betta pharmaceutical and founder of Betta fund, delivered a welcome speech at the meeting. He pointed out that in recent years, while accelerating its own development, Betta pharmaceutical is also trying to help the industrialization of high-quality innovation projects. E-nitiate Biopharmaceuticals focuses on the research and development of new drugs for autoimmune diseases, with good development prospects and great development potential. In the future, Betta pharmaceuticals and Betta fund give full support to the development of E-nitiate Biopharmaceuticals and help E-nitiate Biopharmaceuticals develop into an excellent pharmaceutical innovation enterprise
Speech by Dr. Ding lieming
Dr. Shen Wang, chairman and chief scientist of E-nitiate Biopharmaceuticals, said in his speech that Yuhang Economic and Technological Development Zone is a fertile land for innovation and entrepreneurship. It is a great honor for E-nitiate Biopharmaceuticals to successfully settle here. At the same time, I would like to thank Betta fund for its support to E-nitiate Biopharmaceuticals. As a new force in the biomedical industry,E-nitiate Biopharmaceuticals will take to Betta Pharmaceuticals as an example and take root in Yuhang, E-nitiate Bio will strive to build and take part in the high-quality development of Yuhang Economic and Technological Development Zone, and contribute to the development of biomedical industry in Yuhang District.
Speech by Dr. Shen Wang
At
the meeting, Mr. Shi Keqi, member of the Party Working Committee and
deputy director of the Management Committee of Yuhang Development Zone,
and Dr. Shen Wang, chairman and chief scientist of E-nitiate
Biopharmaceuticals, carried out the settlement signing ceremony on
behalf of both parties.
Signing ceremony of E-nitiate Biopharmaceuticals settled in Yuhang Development Zone
Dr.
Shen Wang, chairman and chief scientist of E-nitiate
Biopharmaceuticals, and Mr. Fan Jianxun, vice president and chief
financial officer of Betta pharmaceutical, respectively held the
strategic investment signing ceremony with Betta fund on behalf of
E-nitiate Biopharmaceuticals.
Signing ceremony of strategic investment of E-nitiate Biopharmaceuticals Betta fund
Signing ceremony
E-nitiate Biopharmaceuticals is located in Hangzhou where the beautiful Xizi lake resides. The company is committed to the research and development of new drugs for autoimmune diseases. The core team is led by Dr. Shen Wang, a senior scientist, and composed of many overseas returnees with rich experience in clinical development and commercialization. The company has a number of innovative drugs independently developed, and the clinical application of QY201 in the R&D pipeline is imminent. Recently, the company obtained tens of millions of yuan in angel round investment from Betta fund.
The national Hangzhou Yuhang Economic and Technological Development Zone was established in 1993. It has a national enterprise incubator, a provincial high-tech industrial park, Zhejiang's only biomedical high-tech industrial park and the first intelligent manufacturing demonstration base in Zhejiang Province. After more than 20 years of development, the development zone has gathered two characteristic leading industries of high-end equipment manufacturing and bioeconomy. The development zone boasts with a total of nearly 300 large-scale enterprises, more than 220 National high-tech enterprises, 14 listed enterprises, and introduced more than 500 high-level talents. Its comprehensive strength has been steadily improving year by year.
Betta biomedical industry fund is an equity investment fund initiated and established by Dr. Ding lieming, chairman and CEO of Betta Pharmaceutical Co., Ltd, Dr. ding is as the main sponsor, and the managing enfity is Hangzhou Beijia Investment Management Co., Ltd. The fund focuses on the general health industry, focusing on biomedicine, in vitro diagnosis, innovative medical devices and other fields. The fund takes the industry's top experts and leaders in the pharmaceutical industry as the core, and with the help of the core team's deep experience and resources in R & D, industrialization and other subdivided fields, it provides full-stage assistance for investment enterprises.
